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Polyunsaturated fatty acids inhibit the expression of
hepatic glucose-6-phosphate dehydrogenase (G6PD) by
changes in the amount of G6PD pre-mRNA in the nucleus in the absence of changes in the transcription rate
of the gene. We have compared the nuclear accumulation of partially and fully spliced mRNA for G6PD in the
livers of mice fed diets high versus low in polyunsaturated fat. Consumption of a diet high in polyunsaturated
fat decreased the accumulation of partially spliced
forms of the G6PD pre-mRNA. Examining the fate of
multiple introns within the G6PD primary transcript
indicated that in mice fed a high fat diet, G6PD
pre-mRNA containing intron 11 accumulated within the
nucleus, whereas G6PD mature mRNA abundance was
inhibited 50% or more within the same livers. Transient
transfection of RNA reporters into primary hepatocyte
cultures was used to localize the cis-acting RNA element
involved in this regulated splicing. Reporter RNA produced from constructs containing exon 12 were decreased in amount by arachidonic acid. The extent of
this decrease paralleled that seen in the expression of
the endogenous G6PD mRNA. The presence of both exon
12 and a neighboring intron within the G6PD reporter
RNA was essential for regulation by polyunsaturated
fatty acid. Inhibition was not dependent on the presence
of the G6PD polyadenylation signal and the 3ⴕ-untranslated region, but substitution with the SV40 poly(A) signal attenuated the inhibition by arachidonic acid. Thus,
exon 12 contains a putative splicing regulatory element
involved in the inhibition of G6PD expression by polyunsaturated fat.

Polyunsaturated fatty acids are potent regulators of cellular
metabolism. As components of phospholipids, they are involved
in signal transduction from specific plasma membrane receptors and are precursors for the synthesis of eicosanoids. When
present in the diet of animals or the medium of cells in culture,
polyunsaturated fats can both increase and decrease the activity or amount of specific cellular proteins. In this regard, polyunsaturated fatty acids have long been known to decrease the
capacity of liver cells to synthesize fatty acids de novo.
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The pathway of de novo fatty acid biosynthesis is essential
for the conversion of energy substrates, such as glucose, which
are in excess of immediate needs, to fatty acids that can be
stored as triacylglycerols. This pathway is most active in liver
and adipose tissue and involves a family of enzymes referred to
as the lipogenic enzymes (for review, see Ref. 1). These enzymes include ATP-citrate lyase, acetyl-CoA carboxylase, fatty
acids synthase, malic enzyme, and glucose-6-phosphate dehydrogenase (G6PD).1 Consistent with their role in energy metabolism, the activities of these enzymes are induced when
animals are fed a high carbohydrate diet and decreased during
starvation. Likewise, lipogenic enzyme activity is decreased by
a high fat diet, particularly a diet rich in polyunsaturated fatty
acids. Regulation of the activities of ATP-citrate lyase, acetylCoA carboxylase, fatty acid synthase, and malic enzyme involves changes in the rate of transcription of these genes (2–7).
In general, these changes in transcription rate fail to account
for the magnitude of change in the amount of mRNA for these
enzymes. Thus, posttranscriptional regulation has been proposed as an additional mechanism to account for the regulation
of the amount of some of these enzymes (6, 8). Regulation of the
expression of G6PD is in sharp contrast to other members of
the lipogenic enzyme family in that starvation, refeeding, and
dietary polyunsaturated fat result in large changes in the
amount of G6PD mRNA but do not regulate the transcriptional
activity of the G6PD gene (9).
Posttranscriptional regulation of gene expression can occur
at multiple steps during RNA processing or by changes in the
stability of the mature mRNA. The processing of the nascent
transcript to the mature mRNA includes the addition of the
5⬘-m7GppG cap, splicing, and 3⬘-end formation. The correct
processing of an mRNA is essential for its release from the site
of transcription and export to the cytoplasm (10 –12). Thus, the
efficient and complete maturation of mRNA is a potential control point of gene expression. Previous studies in our laboratory
have characterized the posttranscriptional regulation of G6PD
by dietary factors. The dietary paradigm of starvation then
refeeding causes a 15-fold or more increase in G6PD mRNA
abundance. Regulation of G6PD mRNA abundance during the
refeeding of starved mice is caused by an increase in the rate of
spliced RNA accumulation in the nucleus (13). The increase in
spliced RNA accumulation cannot be accounted for by the rate
of accumulation of polyadenylated RNA nor does it involve
changes in the length of the poly(A) tail. Thus, the G6PD gene
is transcribed at a continuous and unchanging rate, and the
amount of mature G6PD mRNA produced is regulated during
1
The abbreviations used are: G6PD, glucose-6-phosphate dehydrogenase; CMV, cytomegalovirus; RSV, Rous sarcoma virus; CAT, chloramphenicol acetyltransferase; pre-mRNA, precursor mRNA; UTR, untranslated region.
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the splicing of the primary transcript to the mature mRNA.
The absence of transcriptional regulation of G6PD makes it an
ideal model to study this unique posttranscriptional mechanism. We asked if inhibition of G6PD expression by polyunsaturated fatty acids occurs at the same step as positive regulatory stimuli.
In liver, G6PD activity and mRNA amount decrease 80% in
mice consuming a diet high in polyunsaturated fat versus those
fed a low fat diet (9). The decrease in cytoplasmic RNA is
preceded by a similar decrease in the amount of mRNA in the
nucleus (14). This effect of dietary fat is recapitulated in hepatocytes in primary culture. In this regard, incubation of primary rat hepatocytes with arachidonic acid results in a parallel
decrease in the amount of G6PD enzyme activity and mRNA
abundance in the absence of a change in the transcriptional
activity of the gene (15). Similar to the inhibition by dietary fat,
the decrease in G6PD mRNA by arachidonic acid is preceded by
a decrease in the amount of mRNA in the nucleus (15). Thus,
inhibition of G6PD expression by polyunsaturated fatty acids
occurs in the nucleus and is the result of the intracellular
actions of fatty acids. Determining the molecular details of this
regulation will provide new information on the breadth of
mechanisms by which nutrients control gene expression.
In this paper, we present data that define a new mechanism
by which polyunsaturated fats inhibit gene expression. We
demonstrate that inhibition of G6PD expression involves a
decrease in the rate of splicing of the G6PD RNA transcript.
Using intact mice, we have identified a slowly spliced intron,
intron 11, in mice consuming a high fat diet. We have extended
these results using primary rat hepatocytes and have demonstrated that transcripts from pre-mRNA reporters containing
exon 12 and a neighboring intron are inhibited by polyunsaturated fatty acids in a manner quantitatively similar to the
endogenous gene.
EXPERIMENTAL PROCEDURES

Animal Care and Cell Culture—Male C57BL/6 mice 4 weeks of age
were obtained from Charles River Corp. Mice were adapted to reverse
cycle room (lights on 7:00 p.m., lights off 7:00 a.m.) for 7 days while
maintained on standard chow diet. Mice were switched to a purified
basal diet containing 58.43% by weight glucose, 16.45% celufil, 4% salt
mix, and 0.02% vitamin mix (Amersham Biosciences) supplemented
with 1% (low fat) or 6% (high fat) by weight polyunsaturated fat in the
form of safflower oil (Sigma) for 7 days. Mice were sacrificed, and
nuclear RNA was isolated at the times indicated in the figures.
Male Sprague-Dawley rats (⬃200 g from Harlan Laboratories, Indianapolis, IN) fed a standard chow diet (Harlan Teklad) were used for all
experiments. Rats were starved for 16 h, refed the high glucose, fat free
diet for 8 h, and then starved for 16 h before use as hepatocyte donors.
Hepatocytes were isolated by a modification of the technique of Seglen
(16) as previously described (15). Hepatocytes (3.3 ⫻ 106) were placed in
60-mm dishes coated with rat tail collagen in Hi/Wo/Ba medium (Waymouth’s MB752/1 plus 20 mM HEPES, pH 7.4, 0.5 mM serine, 0.5 mM
alanine, 0.2% bovine serum albumin) plus 5% newborn calf serum
(37 °C, 5% CO2). Cell viability in all experiments was 90% or greater as
estimated by trypan blue (0.04%) exclusion. After 3– 4 h, the medium
was replaced with serum-free medium. After an additional 16 h of
incubation, the medium was replaced with medium containing the
treatments indicated in the figure legends and a Matrigel overlay (0.3
mg/ml; BD PharMingen) (17). Subsequently, the medium was changed
every 12–24 h to one of the same composition but without Matrigel.
Arachidonic acid (Nu-Check Prep, West Elysian, MN) was bound to
bovine serum albumin (18). The fatty acid (4 mM), albumin (1 mM)
stocks contained butylated hydroxytoluene (0.01%), and the medium
contained ␣-tocopherol phosphate, disodium (10 g/liter), to minimize
oxidation of fatty acids.
Transfection was done using Lipofectin following the manufacturer’s
protocol (Invitrogen) and using 2– 4 g of test DNA and 1 g of RSV
CAT to control for transfection efficiency. The ratio of DNA to liposome
reagent was 1:6.7 in all experiments. Transfection was begun after 4 h
of culture, and the transfection medium remained on the hepatocytes
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for 16 h. In transfection experiments the Matrigel overlay was added
4 h after the transfection began (17).
Constructs for Transfection—Plasmids used in the analysis of cisacting elements in the G6PD primary transcript were made using
pGL3-Basic (Promega Corp., Madison, WI) as the vector backbone. The
luciferase gene was removed from this vector, and portions of G6PD
genomic DNA or the G6PD cDNA were inserted in its place. Either the
CMV promoter/enhancer sequences (1– 640 bp from the pCMV␤ vector,
CLONTECH) or the G6PD promoter sequences (⫺780 to ⫹3) were
inserted into the multiple cloning site to drive expression of the test
sequences. The plasmids contained either the SV40 polyadenylation
signal provided in the plasmid or the G6PD polyadenylation signal. The
RSV CAT plasmid used to control for transfection efficiency was constructed using the pCAT3 Basic vector (Promega) and inserting the
RSV long terminal repeat from pRSV CAT (19).
Isolation of Total RNA and Northern Analysis—Total RNA from 2–3
plates per treatment was isolated by the method of Chomczynski and
Sacchi (20). Quantitation of RNA using Northern analysis was done as
previously described (9).
Isolation of Nuclear RNA—Nuclei from liver were isolated by a
modification (13) of the method of Leppard and Shenk (21). This protocol results in the isolation of nuclear RNA that is in the processing
pathway and is essentially devoid of cytoplasmic contamination (13). In
later experiments using probes with two introns (Figs. 3 and 4), the
DNase I digestion and high salt extraction steps were eliminated because these probes permit the detection of pre-mRNA at two different
steps in splicing. The absence of cytoplasmic contamination in this
fraction was assessed as described (13). Cytoplasmic RNA in the nuclear RNA preparations was less than 1%.
Probe Design and Ribonuclease Protection Assay—The following
probes were designed for use in the ribonuclease protection assay (Fig.
1). The exon 2-intron 2 (E2-I2) and exon 8-intron 8-exon 9-intron 9
(pBG2) probes have been previously described (13). Probes to intron
6-exon 7-intron 7-exon 8 (pBG1) and exon 10-intron 11 (p200) were
constructed by subcloning G6PD genomic DNA into pBluescript KS⫹
(Stratagene, La Jolla, CA). An additional probe, pJW1, was designed
that hybridized to exon 10-intron 10-exon 11-intron 11 and exon 12. The
template for this probe was synthesized from a genomic subclone by
PCR amplification. The 5⬘ primer was 5⬘-CGGAATTCAACTTATGGCAACAG-3⬘; the underlined sequence is an EcoRI site for subcloning
followed by G6PD exon 10 sequence. The 3⬘ primer was 5⬘-AAGGATTCCTCTCGATCAATCTTG-3⬘; the underlined sequence is a BamHI
site for subcloning followed by G6PD exon 12 sequence. After amplification, the DNA was subcloned into pBluescript KS⫹, and the authenticity of these sequences was verified by sequencing.
Two templates were designed for use in ribonuclease protection assays with RNA from transfected rat hepatocytes. Rat and mouse G6PD
exon 13 templates were synthesized by PCR amplification of genomic
DNA. These probes were targeted to a region of exon 13 that contains
substantial mismatch between the rat and mouse sequences. In this
way the rat probe detects mRNA produced from the endogenous G6PD
gene but not the transfected gene, whereas the mouse probe detects
mRNA produced from the transfected DNA and not the endogenous
gene. The primer pairs for the rat template were 5⬘-CGGAATTCTGGAGGGACAATGACCAAACC-3⬘ and 5⬘-CGCGGATTCCGGTTGGATGAGGCTGACTATGGAC-3⬘, where the single and double underline
represent EcoRI and BamHI restriction sites, respectively. The fragment was subcloned into pBluescript KS⫹ and sequenced. The mouse
exon 13 template was as previously described (14). Templates for probes
to rat ␤-actin, CAT, and 18 S were purchased from Ambion, Inc.
(Austin, TX). All templates were linearized before use in the in vitro
transcription reaction.
Antisense RNA probes were synthesized in an in vitro transcription
reaction. The probe and RNA were hybridized at 45 °C overnight, and
RNase digestion was as previously described (14). The resulting hybridization products protected from RNase digestion were separated in a 5%
denaturing polyacrylamide gel. The gel was dried and placed in a
storage phosphor cassette for 1–3 days. Images were quantified using
ImageQuant software by Molecular Dynamics (Amersham Biosciences).
In Figs. 2– 4, the units obtained from the image analysis were expressed
per number of cytosines in the protected fragment to permit comparison
of the amount of RNA between fragments of different size.
RNA from hepatocytes that had undergone transient transfection
frequently contained significant amounts of residual plasmid DNA.
Because this DNA would also bind to probes and result in protected
fragments of the same size as the target RNA, the contaminating DNA
was eliminated by digestion of the RNA with RNase-free DNase 1 (10
units/10-g aliquot of hepatocyte RNA in 10 mM Tris, pH 7.5, 25 mM
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MgCl2, 5 mM CaCl2) for 30 min at 37 °C before hybridization with the
radioactive probes.
RESULTS

Inhibition of the Accumulation of G6PD-spliced mRNA by
Dietary Polyunsaturated Fat—To investigate if dietary polyunsaturated fatty acids inhibit the efficiency of splicing of the
G6PD transcript, we compared the amount of unspliced and
spliced G6PD mRNA in the livers of mice fed the low fat versus
the high fat diet. The amount of hepatic G6PD mRNA varies in
amount in response to the normal feeding behavior of the
mouse. Mice eat during the dark cycle and are relatively inactive during the light cycle. At the start of the dark cycle, the
level of G6PD mRNA is very low. As the mice consume the low
fat diet, the amount of G6PD mRNA increases 7-fold or more
(14); this increase occurs after a lag of 2– 4 h. As the light cycle
begins, the amount of G6PD mRNA decreases, returning to a
very low level. Consumption of a diet high in polyunsaturated
fat results in a 50% decrease in the amount of hepatic G6PD
mRNA at the beginning of the dark cycle, and an attenuation of
the feeding induced increase to less than 2-fold (14). We reasoned that the continued increase in G6PD mRNA in the livers
of mice fed a high fat diet reflected the stimulation in gene
expression due to the carbohydrate in the diet. Thus, to measure only gene expression effects due to dietary fat, we measured G6PD mRNA abundance during the first 4 h of the feeding
cycle, a time before the major increase in mRNA accumulation.
RNA was isolated from both the cytoplasm and the nuclear
insoluble fractions of mouse liver after the animals were
adapted to either a low fat or a high fat diet for 7 days. The
nuclear insoluble fraction is enriched in nascent RNA being
transcribed and undergoing RNA processing (22–24). Two
probes separated by 12 kilobases were used to detect G6PD
RNA (Fig. 1, E2-I2 and p200 probes). Each probe hybridized
across an exon/intron junction and, thus, measured G6PD RNA
that contained that intron and RNA from which that intron had
been spliced. The protected fragments are referred to as unspliced and spliced RNA, respectively, even though both protected fragments represent a mix of RNA containing one or
more of the G6PD 12 introns.
Feeding mice a high fat diet resulted in a 60 –70% decrease in
the amount of spliced G6PD RNA in both the nuclear and
cytoplasmic fractions of mouse liver (Fig. 2, 0 h time point).
Between 0 and 2 h of feeding, the amount of unspliced RNA
(E2-I2 protected fragment) in the nucleus remained very low
and was not different between mice fed the high fat and the low
fat diet. This lack of difference in the amount of pre-mRNA is
consistent with our previous data demonstrating that transcription of the G6PD gene is not regulated by polyunsaturated
fat (9). By 4 h, the amount of G6PD unspliced mRNA had
increased in mice fed the low fat diet, whereas in mice fed the
high fat diet, the amount of unspliced mRNA remained at a low
basal level. At all time points, the amount of spliced RNA (E2
protected fragment) in the nucleus was 5–10-fold greater than
the amount of unspliced RNA; however, this increase in the
amount of spliced RNA was attenuated at all time points by
the high fat diet. The changes in the amount of spliced RNA in
the nucleus were similar to the changes in the amount of
mature mRNA in the cytoplasm. Furthermore, the specific
activity (phosphorimaging units/number of cytosines) of the
spliced RNA was the same in both the cytoplasmic and nuclear
pools, consistent with our previous results demonstrating that
G6PD regulation by polyunsaturated fatty acids occurs in the
nucleus (14). Similar results were obtained with a probe (p200)
that hybridizes to the exon 10-intron 10 splice junction of the
G6PD RNA (data not shown).
The decrease in the amount of spliced RNA in the nucleus

FIG. 1. Probes and protected fragments used in ribonuclease
protection assays with mouse RNA. The lines and boxes schematically depict the structure of the pre-mRNA. To the left of the schematic
are the working names for each of the probes. Depicted beneath the
pre-mRNA structure are the protected fragments that are detected with
each probe. The largest protected fragment in each group identifies
pre-mRNA that is “unspliced.” Protected fragments retaining one of the
two introns are referred to as “partially spliced” RNA. “Spliced” RNA is
quantified using the protected fragments representing only the exon
sequences. The riboprobes used to detect these RNA species were 41–90
nucleotides larger than the full-length protected fragment, so that
undigested probe could be discriminated from largest protected
fragment.

could reflect a decrease in the rate of splicing of the primary
transcript or a decrease in the stability of the fully spliced
transcript. To discriminate between these possibilities, the
amount of RNA early in the splicing process was measured
using RNase protection assays and a probe that hybridized
across two introns (exon 8, intron 8, exon 9, and intron 9,
pBG2). Four protected fragments were detected representing
G6PD pre-mRNA that contained both introns (unspliced),
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FIG. 2. Dietary fat inhibits the accumulation of spliced RNA
for G6PD. RNA was isolated from the cytoplasm (A) and the nuclear
insoluble (B) fractions of mouse liver after adaptation to a high fat or
low fat diet. Zero hour represents the start of the feeding (dark) cycle.
The isolated RNA (20 g) was analyzed by RNase protection assay
using the exon 2-intron 2, depicted in Fig. 1. The amounts of the
unspliced (exon 2-intron 2, E2-I2) and spliced (exon 2, E2) RNase
protection products were imaged and quantified using phosphorimaging and ImageQuant software. Each point represents the mean ⫾ S.E.
(n ⫽ 4 mice). The values are the ImageQuant units normalized for the
C content of the protected fragment (PI Un/# C). Each RNase protection assay also included a probe for 18 S rRNA to detect any loss of RNA
during the assay or error in quantitation. No difference was observed in
the amount of 18 S RNA in each sample. The significance of the
differences between G6PD E2 mRNA abundance in the high fat versus
the low fat nuclear samples was analyzed using analysis of variance.
Dietary fat caused a significant decrease in spliced mRNA abundance in
the nucleus (p ⬍ 0.0001). Identical results were obtained in a separate
experiment using the p200 probe (Fig. 1) for the exon 10-intron 10
region of the pre-mRNA (data not shown).

pre-mRNA that had only intron eight spliced (partially spliced),
and two fragments representing G6PD RNA that had both
introns removed (fully spliced). Protected fragments corresponding to spliced introns were not detected. At 0 h, the
amount of unspliced RNA was similar in mice fed both the low
fat and high fat diets despite a 50% decrease in the amount of
fully spliced RNA (Fig. 3A, overlapping circle and square, and
data not shown). The amount of partially spliced RNA was
greater at all time points than the amount of unspliced RNA.
As the mice consumed the low fat diet, the amount of partially
spliced RNA increased 7– 8-fold, whereas only a 2–3-fold increase in partially spliced RNA was observed in mice fed the
high fat diet. The attenuation of partially spliced mRNA accumulation with the high fat diet resulted in a decrease in the
ratio of partially spliced to unspliced RNA between the two
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FIG. 3. Inhibition of G6PD mRNA abundance by dietary fat
occurs early in splicing. RNA was isolated from the nucleus of mouse
liver after adaptation to the high fat or low fat diet. Zero hour represents the start of the feeding (dark) cycle. A, the isolated RNA (30 g)
was analyzed by RNase protection assay using the pBG2 probe, depicted in Fig. 1. The amounts of unspliced (exon 8-intron 8-exon 9-intron 9) and partially spliced (exon 8-exon 9-intron 9) RNase protection
products were imaged and quantified using phosphorimaging and ImageQuant software. Each point represents the mean ⫾ S.E. (n ⫽ 3
mice). The values are the ImageQuant units normalized for the C
content of the protected fragment (PI Un/# C). These data are representative of two independent experiments, which showed similar results. B, the amounts of the partially spliced and unspliced RNA were
quantified for each separate mouse at each time point in the experiment
in A. The values were normalized for C content, and the ratio of
partially spliced/unspliced RNA was calculated. Each value is the
mean ⫾ S.E. of n ⫽ 3 mice. C, the nuclear RNA was analyzed using
RNase protection assays, and the pBG1 probe is depicted in Fig. 1. The
amount of partially spliced RNA (intron 6-exon 7-exon 8) was quantified
and expressed as described above. HF, high fat; LF, low fat.

dietary groups (Fig. 3B). Thus, dietary polyunsaturated fat
caused a decrease in the accumulation of partially spliced RNA.
These data are consistent with regulation at an early step in
RNA processing rather than a change in stability of the mature
mRNA in the nucleus.
A decrease in the ratio of the amount of partially spliced to
unspliced RNA in mice fed the high fat diet compared with the
low fat diet could indicate that the splicing reaction itself is
inhibited by dietary polyunsaturated fatty acids. In such a case
the improperly spliced RNA would be targeted for degradation
in the nucleus (11, 12). Thus, we examined other intron-exon
boundaries to determine whether any intron was selectively
retained in the G6PD transcript when mice were consuming a
high fat diet. A probe to intron 6, exon 7, intron 7, and exon 8
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(pBG1) detected RNA with both introns present, RNA from
which intron only 7 has been spliced and RNA from which both
introns are removed. Partially spliced RNA representing retention of intron 6 increased 3-fold in mice fed the low fat diet (Fig.
3C). Consumption of the high fat diet attenuated the accumulation of this partially spliced RNA, consistent with the previous results.
A distinctly different result was obtained when a probe was
used to the exon 10, intron 10, exon 11, intron 11, and exon 12
(pJW1) region of the pre-mRNA. Use of this probe with nuclear
RNA resulted in protected fragments representing RNA containing both intron 10 and 11, RNA from which intron 10 had
been spliced, RNA from which intron 11 had been spliced, and
RNA from which both introns had been removed. Thus two
partially spliced RNA intermediates were detected in contrast
to the results with other probes where the partially spliced
RNA consistently contained only one of the two introns represented in the probe (Fig. 4A). Even more striking was the
increase in abundance of partially spliced RNA containing intron 11 in mice fed the high fat diet (Fig. 4B, NoI/O HF bars).
The increase in abundance of this partially spliced RNA occurred despite a decrease of 61% or more in fully spliced RNA
detected in the nucleus (Fig. 4A, exon 11 and 12 bands, and
data not shown for the other time points). Likewise, the
amount of unspliced RNA increased with time in mice fed the
low fat diet, and this increase was inhibited in mice fed the
high fat diet. This result was reproducible both between mice
within a single experiment and between different experiments
with different groups of mice. In the mice fed the high fat diet,
the pre-mRNA retaining intron 11 must ultimately be degraded since the amount of fully spliced RNA (protected fragments representing exons 11 or 12) was decreased within the
same aliquot of RNA (Fig. 4A). These results are consistent
with a decrease in the efficiency of pre-mRNA splicing in mice
fed a high fat diet.
Inhibition of G6PD pre-mRNA Reporter Expression in Primary Rat Hepatocytes—Incubation of rat hepatocytes in primary culture with arachidonic acid results in a decrease in the
expression of the G6PD gene similar to the decrease observed
in intact animals due to dietary polyunsaturated fatty acids.
This inhibition is caused by a decrease in the amount of G6PD
pre-mRNA in the nucleus in the absence of changes in the
transcriptional activity of the gene (15). We used primary hepatocytes to determine whether arachidonic acid would inhibit
the amount of RNA expressed from pre-mRNA reporter constructs expressing G6PD RNA. Each pre-mRNA reporter contained the CMV promoter. Included in the transfections was a
reporter plasmid containing the RSV promoter and the CAT
gene, which served as an internal control for transfection efficiency. In general, variation in CAT expression was less than
10% between treatments (data not shown). To determine that
the activity of the CMV promoter was not regulated by arachidonic acid, rat hepatocytes were transfected with CMV ␤-galactosidase and incubated with and without arachidonic acid.
Incubation of the hepatocytes with arachidonic acid did not
regulate either the amount of ␤-galactosidase mRNA (Table I)
or enzyme activity (data not shown). Likewise, the amount of
CAT mRNA was the same between treatments, indicating that
transfection efficiency was similar with and without arachidonic acid. The 40 –70% decreases in the amount of endogenous
G6PD mRNA indicated that the hepatocytes were responsive to
arachidonic acid. Thus, the activity of the CMV promoter was
not regulated by arachidonic acid.
The G6PD gene is 18 kilobases long and contains 13 exons.
To test for cis-acting elements in the RNA, plasmids were
constructed containing different pre-mRNA reporters repre-

FIG. 4. Pre-mRNA containing intron 11 selectively accumulates in mice fed the high fat diet. RNA isolation and the dietary
protocol were as described in Fig. 3. The isolated RNA (30 g) was
analyzed by RNase protection assay using the pJW1 probe, depicted in
Fig. 1. A, a representative assay is shown. The size and structure of the
protected fragments are shown on the right of the figure. Single lines
represent introns, and rectangles represent exons. Each lane represents
RNA from a single mouse from the 2-h time point shown in B. This
assay is representative of two separate experiments and nuclear RNA
preparations. B, RNase protection products representing unspliced and
partially spliced RNA were quantified using ImageQuant software.
Each bar represents the mean ⫾ S.E. of n ⫽ 4 mice with the exception
of the 4-h low fat bars, which are n ⫽ 3 mice. The phosphorimaging
units were normalized for the C content of the fragment (PI Un/# C).
The identity of the bars is listed on the right of the figure. HF, high fat;
LF, low fat; FL, full-length protected fragment.

senting subsets of the 18-kilobase gene (Fig. 5). An additional
mRNA reporter was constructed that contained the full-length
cDNA for G6PD. The genomic DNA and the cDNA were both of
murine origin and were transfected into rat hepatocytes. Exon
13 sequences differ sufficiently between rats and mice such
that RNase protection assays and a riboprobe to this region
could be used to distinguish between transcripts produced from
the pre-mRNA reporter plasmid and from the endogenous
mRNA (Fig. 6). In all transfected cells, the amount of endogenous G6PD mRNA was decreased 40% or more due to incubation with arachidonic acid. Expression of ␤-actin mRNA was
not regulated, indicating that changes in G6PD mRNA accumulation in the hepatocytes was not due to a generalized effect
of arachidonic acid on gene expression.
A pre-mRNA reporter containing DNA between intron 6 and
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TABLE I
The activity of the CMV promoter is not regulated by arachidonic acid in rat hepatocytes
Experiment

1
2
3

Treatment

G
G
G
G
G
G

⫹
⫹
⫹
⫹
⫹
⫹

I
I ⫹ FA
I
I ⫹ FA
I
I ⫹ FA

␤-Galactosidase

CAT

G6PD

30.5 ⫾ 4
28.9 ⫾ 4
82.7 ⫾ 8
77.4 ⫾ 11
82.5 ⫾ 2
75.9 ⫾ 1

75.4 ⫾ 23
69.3 ⫾ 18
382.5 ⫾ 5
413.5 ⫾ 22
25.9 ⫾ 1
30.9 ⫾ 2

12.2 ⫾ 2
2.9 ⫾ 0.5
32.6
18.9
72.5
26.7

Isolated hepatocytes were cotransfected with pCMV␤ and pRSV -CAT in experiments 1 and 2 and with pCMV-GL3-gal and pRSV -CAT in
experiment 3. Total RNA was isolated after 24 h with the indicated treatments, and the amounts of ␤-galactosidase, CAT, and G6PD mRNA were
measured. The values are the mean ⫾ S.E. for n ⫽ 3 plates; the actual numbers from ImageQuanT were multiplied by 10⫺4 for ease of reporting.
The absence of a S.E. indicates only n ⫽ 2 plates were assayed. G, glucose (25 mM); I, insulin (0.1 M); FA, arachidonic acid (250 M).

FIG. 5. Structure of the G6PD pre-mRNA reporters used in transfection assays. Portions of G6PD genomic DNA or the cDNA were
subcloned into the pGL3-Basic vector as described under “Experimental Procedures.” The DNA was of mouse origin. Either the CMV promoter or
the G6PD promoter drove transcription of the reporter RNA. The HindIII (H) site represents the start of genomic DNA in the plasmids containing
exons 7–13. In the remaining plasmids this site represents regions of the G6PD 5⬘-flanking DNA beginning at base ⫺9. The EcoR1 (E), SmaI (S),
and Alf2 sites are present in the genomic DNA 3⬘-end of the G6PD gene and represent the 3⬘-end of the inserted DNA. Gray-shaded rectangles
represent G6PD exons. The black-shaded portions of the rectangles represent the portion of exon 13. which is the 3⬘-UTR. The XbaI (X) site is 136
nucleotides from the 3⬘-end of exon 13. The sizes in the figure are approximate.

the 3⬘-end of the gene was robustly expressed in rat hepatocytes incubated with insulin and glucose (Fig. 6). This plasmid
contains exon 11, intron 11, exon 12, and intron 12 the region
implicated in the decreased splicing efficiency by the high fat
diet in mouse liver. Incubation of the rat hepatocytes with
arachidonic acid resulted in a 51% decrease in the level of this
reporter transcript. Expression of the CAT mRNA was similar
between the treatments; thus, the decrease was not a consequence of differences in transfection efficiency or a generalized
effect on expression of transfected plasmids. The decrease in
the reporter transcript expression was similar to the decrease
in the amount of rat G6PD mRNA, indicating that the regulation of reporter transcript expression mirrored the regulation
of the endogenous G6PD gene.
Regulated splicing can involve interactions between splicing
regulatory elements within the regulated exon or intron and
regulatory elements in the promoter or 3⬘-UTR. We next tested if
the regulated expression of this reporter pre-mRNA is retained in
the context of a different promoter or polyadenylation signal. A
derivative of the original plasmid reporter (pCMV7–13, 3⬘-UTR)
was made in which the CMV promoter was replaced with the
G6PD promoter (pG6PD7–13, 3⬘-UTR). The amount of reporter

RNA was decreased by arachidonic acid when the G6PD promoter drove production of the reporter RNA (Fig. 7). This confirmed that the CMV promoter was not causing the arachidonic
acid-induced decrease in mRNA amount. A second derivative
involved replacement of 137 nucleotides of the 3⬘-UTR and the
entire downstream genomic DNA with the SV40 polyadenylation
signal (pCMV7–13, SV40). When the amount of reporter transcript was measured in hepatocytes transfected with this plasmid (pCMV7–13, SV40), the inhibition by arachidonic acid was
attenuated (Fig. 7). However, the amount of the reporter transcript was decreased 14.5%, suggesting that this region of the
G6PD 3⬘-UTR may augment the regulation but was not required
for inhibition by arachidonic acid.
It is possible that the presence of any G6PD intron could be
involved in the inhibitory effect of arachidonic acid on the
expression of these reporter RNAs. To test this, a pre-mRNA
reporter was constructed that contained introns 3 and 4 and
part of 5 within the context of G6PD cDNA sequences (Fig. 5;
pCMV1–5, 3⬘-UTR). After transfection of this reporter into the
rat hepatocytes, the transcripts produced were measured using
the RNase protection assay and reporter-specific probe. Incubation with arachidonic acid did not regulate the level of these
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FIG. 6. Arachidonic acid (20:4) inhibits the accumulation of
G6PD reporter transcripts. Primary rat hepatocytes were transfected by incubation with liposomes and the G6PD pre-mRNA reporter
constructs depicted in Fig. 5 plus RSV CAT as a control for transfection
efficiency. After 14 h of incubation with the DNA-liposome complexes,
the medium was changed to one of the same composition but containing
glucose (25 mM) and insulin (0.1 M) with or without albumin-bound
arachidonic acid (175 M). The hepatocytes were incubated for 24 h with
the treatments, and then total RNA was isolated from three pooled
dishes (60 mm) of hepatocytes. The amounts of reporter transcript and
endogenous mRNA were measured using RNase protection assays and
transcript specific riboprobes. G6PD mouse represents transcripts from
the pre-mRNA reporter; CAT represents transcripts from RSV CAT;
G6PD rat and ␤-actin represent endogenous rat mRNA. The results of
representative experiments are shown. The values beneath the figure
are the percent inhibition due to arachidonic acid and are the mean ⫾
S.E. of separate experiments representing different rat hepatocyte isolations. The amount of G6PD mouse transcript was divided by the
amount of CAT transcript (⫻100) to correct for differences in transfection efficiency. The G6PD rat signal is divided by the ␤-actin signal
(⫻100) to correct for differences in RNA loading. Repetition was as
follows: pCMV7–13, 3⬘-UTR (n ⫽ 7); pCMV1–5, 3⬘-UTR (n ⫽ 3), and
pCMVcDNA, 3⬘-UTR (n ⫽ 3).

reporter transcripts but did decrease endogenous G6PD expression by 60% (Fig. 6). Thus, regulation of G6PD expression
requires RNA sequences between intron 6 and the end of the
gene and not merely the splicing of G6PD introns. A similar
result was observed when the expression of an RNA reporter
containing only the cDNA sequences were measured (Fig. 6;
pCMVcDNA). Substitution of the G6PD promoter for the
CMV promoter failed to reconstitute the inhibition (Fig. 7;
pG6PDcDNA). These results indicate that inhibition of G6PD
mRNA accumulation by arachidonic acid requires introns that
are 3⬘ of intron 6. This suggests that the functional assay in rat
hepatocytes recapitulates the regulated splicing observed in
intact mice fed a high fat diet.
To further localize the RNA element involved in inhibition of
G6PD expression by arachidonic acid, a series of deletion constructs were made using unique restriction sites in this region
of the genomic DNA. Pre-mRNA reporters containing successively smaller regions of the G6PD transcript were constructed
and transfected into primary rat hepatocytes (Fig. 8). All constructs contain the same 91 nucleotides downstream of the
TATA box in the CMV promoter, which were also present in the
previous reporter constructs. RNA from the reporter constructs
was readily detected in the RNase protection assays. The
amount of reporter RNA was decreased by incubation with
arachidonic acid in all constructs that contained sequences

FIG. 7. Inhibition of G6PD reporter RNA expression does not
require the G6PD promoter or 3ⴕ-UTR. Primary rat hepatocytes
were transfected, and the reporter RNA was analyzed as described in
the legend to Fig. 6. G6PD mouse represents mRNA produced from the
RNA reporters, and G6PD rat represents mRNA produced from the
endogenous gene. The protected fragment resulting from RNA produced
from pCMV7–13, SV40 is smaller than the reporters containing the
G6PD 3⬘-UTR and is indicated by the arrow on the left. The band in the
pG6PD7–13, 3⬘-UTR, ⫹20:4 lane is incompletely digested CAT probe.
The values beneath the figure are the percent inhibition due to arachidonic acid and are the mean ⫾ S.E. of n ⫽ 4 separate experiments in the
case of pCMV7–13, SV40, or the average of n ⫽ 2 separate experiments
in the case of pG6PD7–13, 3⬘-UTR and pG6PDcDNA, 3⬘-UTR. The
values in parentheses are the values for the individual experiments. The
amount of G6PD mouse transcript was divided by the amount of CAT
transcript (⫻100) to correct for differences in transfection efficiency.
The G6PD rat signal is divided by the ␤-actin signal (⫻100) to correct
for differences in RNA loading.

between the start of exon 12 through the 3⬘-end of the gene
(Fig. 8). The extent of this inhibition was similar to the inhibition of the endogenous gene. Furthermore, this region of the
gene was able to confer inhibition by arachidonic acid onto a
heterologous RNA, ␤-galactosidase (p␤-gal ex12–13) and to a
portion of the G6PD cDNA (pcDNA ex11–13; Fig. 8). The p␤-gal
ex12–13 construct contained only the last 60 nucleotides of
exon 12, further localizing this element in the exon. In all
experiments the expression of the endogenous ␤-actin mRNA
was not regulated by arachidonic acid, indicating that arachidonic acid did not have a generalized inhibitory effect on cellular metabolism (data not shown). Deletion of exon 12 from
the reporter construct abrogated the inhibition by arachidonic
acid despite a robust inhibition of the endogenous gene (pCMV
in12–13). Thus, a cis-acting RNA element involved in inhibition of G6PD RNA accumulation by arachidonic acid localizes
to exon 12.
DISCUSSION

Dietary polyunsaturated fatty acids are negative regulators
of hepatic lipogenesis that exert their effects both at transcriptional (for review, see Ref. 1) and posttranscriptional (9, 14, 25,
26) steps. The present study is the first to demonstrate that
polyunsaturated fat can inhibit gene expression by decreasing
the rate of splicing of a pre-mRNA to a mature mRNA that can
be exported to the cytoplasm. Our evidence from both mapping
of partially spliced G6PD RNA in the livers of mice and from
the regulation of G6PD RNA reporters in rat hepatocytes indicates that splicing of the G6PD transcript is inhibited by polyunsaturated fatty acids. The decrease in transcript splicing
results in a decrease in the production of mature G6PD mRNA
in these cells. The cis-acting RNA element mapped to exon 12
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FIG. 8. The cis-acting RNA element involved in the inhibition of G6PD expression by arachidonic acid localizes to exon 12. Primary
rat hepatocytes were transfected with the RNA reporter constructs shown in the figure, and the RNA was analyzed as described in the legend to
Fig. 6. Each construct represents successive deletion of genomic DNA, resulting in the production of RNA representing smaller portions of the
G6PD transcript except for p␤-gal ex12–13 and pcDNA 11–13, which represent the region of G6PD genomic DNA containing exon 12 ligated to a
heterologous RNA or the G6PD cDNA, respectively. Hatched boxes represent G6PD exons, and the solid box represents the 3⬘-UTR. All constructs
were driven by the CMV promoter. In these experiments, the hepatocytes were not co-transfected with RSV CAT. The percent inhibition by
arachidonic acid (20:4) for the reporter construct was calculated by dividing the amount of reporter RNA in cells treated with glucose (25 mM) and
insulin (0.1 M) by the amount of reporter RNA in cells treated with glucose, insulin, and arachidonic acid (175 M). All values were normalized
to the amount of 18 S rRNA to correct for differences in total RNA amount. The values for endogenous rat G6PD expression were calculated in the
same manner only using the protected fragment from the rat G6PD probe. The repetition for these experiments was pCMV in7–13 (n ⫽ 3), pCMV
in9 –13 (n ⫽ 3), pCMV ex10 –13 (n ⫽ 9), pCMV ex11–13 (n ⫽ 6), pCMV ex12–13 (n ⫽ 4), pCMV in12–13 (n ⫽ 3) p␤-gal ex12–13 (n ⫽ 4), and pcDNA
11–13 (n ⫽ 3) individual transfection experiments.

of the primary transcript; the activity of this element required
the presence of an intron adjacent to the exon. This does not
appear to be a generalized effect of arachidonic acid on splicing
because the pCMV1–5, 3⬘-UTR construct that contains G6PD
introns 3, 4, and 5 but not exon 12 was not regulated by
arachidonic acid. These results are consistent with the hypothesis than exon 12 contains an exon-splicing enhancer that is
critical for the efficient splicing and ultimate formation of the
mature mRNA. Arachidonic acid would then inhibit the activity of a splicing co-activator that binds this enhancer.
Regulated splicing often involves the activity of splicing enhancer elements in an exon or intron of an RNA. These elements
are involved in the recognition of an exon in the RNA transcript
(27). Most cases of regulated splicing involve alternative exon
inclusion in the mRNA. Enhancer sequences in exons bind regulatory proteins that first define the boundaries of the exon and
then recruit the spliceosome complex (28 –30). These regulatory
proteins are often members of the SR family of splicing activators
(31). The regulated splicing of G6PD does not involve alternative
exon inclusion; however, portions of this pathway may be common. For instance, splicing of G6PD pre-mRNA may require the
presence of a splicing enhancer protein that binds to a sequence
in exon 12 to facilitate spliceosome recruitment to the pre-mRNA.

Proteins involved in splicing have also been demonstrated to
interact with components of the cleavage and polyadenylation
machinery, thereby regulating this step in RNA processing (for
review, see Ref. 32). The definition of a terminal exon involves not
only recognition of the 3⬘-splice site at the start of the exon but
also the polyadenylation signal at the 3⬘-end of the exon (33).
Proteins binding at the polyadenylation site can enhance the
efficiency of splicing of introns in that mRNA. To test if such an
interaction occurred, which was specific to G6PD regulation, the
SV40 polyadenylation signal was substituted for the G6PD signal
and 137 nucleotides of the 3⬘-UTR. The presence of the G6PD
polyadenylation signal alone was not sufficient to result in fatty
acid inhibition of the reporter RNA from all constructs, in that
expression of RNA reporters such as pCMVcDNA, 3⬘-UTR, and
pCMV1–5, 3-UTR that contain the G6PD 3⬘-UTR were not inhibited by arachidonic acid. When the SV40 polyadenylation
signal was included in the context of an RNA reporter containing
intron 6 through exon 13, inhibition of G6PD mRNA by arachidonic acid was still observed, but the inhibition was attenuated
compared with constructs with the intact G6PD 3⬘-end. Thus, the
G6PD polyadenylation signal and/or intact 3⬘-end is not required
for inhibition by arachidonic acid, but an interaction between this
region and the splicing machinery cannot be ruled out. Nonethe-
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less, inhibition of reporter RNA required introns 3⬘ of intron 6 in
the G6PD transcript.
The presumed fate of the G6PD transcript in mice fed the high
fat diet is degradation in the nucleus. Two pathways have been
described for degradation of RNA in the nucleus. In the first
pathway, RNA that is not completely processed does not leave
the site of transcription in the nucleus (10 –12). Specific proteins
recruited to the RNA by the spliceosome complex most likely
mark correct splicing (34 –36). These proteins can then interact
with the export machinery. In the absence of proteins to initiate
export, the RNA can become a target for degradation. What
remains to be determined in a multi-intron transcript is how the
correct and complete splicing of all introns is detected, resulting
in release of the transcript. In yeast, RNA that fails to acquire a
poly(A) tail is retained at or near the transcription site and
degraded by a complex of exonucleolytic enzymes called the nuclear exosome (10, 37). In mammalian cells, SRm160, a member
of the SR family of proteins, promotes splicing, 3⬘-end cleavage,
and nuclear release of transcripts (38). The efficiency of polyadenylation per se does not appear to be a primary determinant
of G6PD mRNA fate (13). Alternatively, G6PD pre-mRNA retaining intron 11 may fail to acquire all the necessary proteins for
release from the transcription site.
A second pathway of nuclear RNA turnover is used in the
degradation of RNA containing premature termination codons.
Certain mRNAs containing premature termination codons are
degraded within the nucleus at the site of their transcription (39).
This nuclear nonsense-mediated decay pathway appears to depend on the presence of either a Kozak consensus sequence in the
mRNA or an internal ribosomal entry site. Scanning in the nucleus by some component(s) of the translational machinery may
detect the premature termination codon and target the mRNA
for degradation (40). Although G6PD mRNA does not contain a
premature termination codon, the G6PD pre-mRNA retaining
intron 11 contains an in-frame stop codon at the start of the
intron and three stop codons within the now out-of-frame exon
12. To be consistent with this nuclear decay pathway, the mRNA
should contain a Kozak consensus sequence. The G6PD
pre-mRNA reporters containing intron 6 to exon 13 sequences or
deletions thereof used in these studies do not contain a sequence
with perfect identity to the Kozak consensus but do contain
several in-frame ATGs, which may provide weak ribosomal entry, sites. Elucidating the further details of this pathway is the
subject of current experiments in the laboratory.
Only a few examples have been reported of changes in the
efficiency of splicing regulating gene expression. These include
thymidylate synthase (41), tumor necrosis factor-␣ (42), and spot
14 (43, 44). Regulated expression of thymidylate synthase during
the cell cycle requires both the thymidylate synthase promoter
and a spliceable intron, which need not be from the thymidylate
synthase RNA (41). In contrast, splicing of the tumor necrosis
factor-␣ mRNA requires a cis-acting element in the 3⬘-UTR of the
transcript (42). Thus, diverse mechanisms appear to be involved
in this regulation. Splicing of the single intron on the spot 14 gene
is enhanced by dietary carbohydrate, refeeding, and insulin (13,
43, 44), but the molecular details of this mechanism are not
known. In addition to the increase in splicing efficiency, the
transcriptional activity of the spot 14 gene is increased by these
treatments (45). Regulating gene expression by both transcriptional and posttranscriptional mechanisms would result in a
more rapid response to nutritional or hormonal changes. Regulation of the efficiency of splicing may be a ubiquitous mechanism
for controlling lipogenic gene expression and may account for the
discrepancies between changes in transcriptional activity and
changes in mRNA abundance for several of these genes. Post-

transcriptional mechanisms for other lipogenic enzymes have
simply not have been studied because of the large transcriptional
changes of many of these genes (for review, see Ref. 1). G6PD
provides an excellent model for these studies because polyunsaturated fat or other nutritional modifications do not regulate the
G6PD promoter. Understanding the details of regulated splicing
will provide new information about the myriad of mechanisms
controlling gene expression.
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